Aeromics
Aeromics is a technology company.
Active
Updated: ·
Financial History
Total Raised
N/A
Valuation
N/A
Aeromics is a technology company.
Aeromics is a clinical-stage pharmaceutical company developing therapeutics based on water physiology to treat severe neurological conditions, primarily cerebral edema from ischemic stroke.[1][4] Its lead product, AER-271, is an intravenously administered aquaporin-4 (AQP4) inhibitor that prevents or arrests brain swelling by targeting molecular water channels, serving patients in neurology and emergency medicine.[1][4] The company has raised $14.07M in Series A funding, achieved first-in-human dosing in trials, and partnered with Simcere for Phase I studies in China as of 2022, indicating clinical momentum despite limited recent public updates.[1][4]
Aeromics was founded in 2008 by scientists Dr. Mitchell H. Rosner and Dr. Walter F. Boron, who identified a therapeutic opportunity while working with aquaporins at Yale School of Medicine.[4][5] Drawing from Nobel Prize-winning research on water channels, they aimed to control edema—particularly in stroke—by inhibiting AQP4, the primary water entry route at the blood-brain barrier.[4] Early milestones included SBIR grants from NIH in 2010 for high-throughput screening, yielding initial hits, and support from Connecticut Innovations, Broadview Ventures, and NINDS to advance to clinical trials.[1][4][5] Headquartered initially in Cleveland, Ohio, and later Branford, Connecticut, the company evolved from preclinical discovery to clinical-stage development.[1][2][4]
Aeromics rides the wave of precision neurology therapeutics, targeting aquaporins amid rising stroke incidence (global leader in disability) and demand for edema control where current options fail.[1][4][5] Timing aligns with advances in water channel biology post-Nobel recognition, enabling first-mover advantage in a market projected for growth via biologics and small-molecule inhibitors.[4] Favorable forces include NIH funding for brain injury, partnerships like Simcere for global trials, and biotech trends toward unmet CNS needs; success could validate aquaporins as new drug targets, influencing stroke care ecosystems and expanding to neurotrauma.[1][4][5]
Aeromics stands poised for Phase II/III trials with AER-271, potentially yielding breakthrough designation for stroke edema if efficacy holds in larger studies.[1][4] Trends like AI-driven drug screening, global partnerships, and CNS investment surges will shape progress, with influence evolving via aquaporin platform expansion to other edemas.[4][5] If validated, it could transform outcomes in ischemic stroke—the top unmet need—echoing its founding vision of harnessing water physiology for life-threatening conditions.[4]